(News Bulletin 247) – Bayer announces participation in a pilot project aimed at reducing or even replacing animal testing using so-called ‘organ on a chip’ (OoC) technology and interactive calculation software .
Supported by esqLABS, Dynamic42, Placenta Lab of the University Hospital of Jena and Bayer’s Consumer Health Division, this project will last one year and aims to develop a platform composed of a microphysiological system (MPS, known as ‘organ-on -chip’) representing the major human tissues involved in drug delivery (liver, intestine, placenta) as well as a pumping system to circulate cell culture media between tissues.
The platform will be digitized to simulate the distribution of compounds and translate the data into human situations.
“While animal testing is often required by regulation in the preclinical phase of new drug development, it can be difficult to translate results from animals to humans in some cases,” Bayer points out.
So, if successful, the platform could help reduce animal testing while improving development outcomes, reducing costs and improving patient safety.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
